scholarly journals Proteomics study of colorectal cancer and adenomatous polyps identifies TFR1, SAHH, and HV307 as potential biomarkers for screening

2021 ◽  
pp. 104246
Author(s):  
Meifang Tang ◽  
Liuhong Zeng ◽  
Zhaolei Zeng ◽  
Jie Liu ◽  
Jie Yuan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Adenomatous Polyps ◽  
Proteomics Study ◽  
Potential Biomarkers

scholarly journals Proteomics study of colorectal cancer and adenomatous polyps identifies TFR1, SAHH, and HV307 as potential biomarkers for screening

2020 ◽  
Author(s):  
Meifang Tang ◽  
Liuhong Zeng ◽  
Zhaolei Zeng ◽  
Jie Liu ◽  
Jie Yuan ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Mass Spectrometry ◽  
Cytochrome P450 ◽  
Malignant Tumour ◽  
Morbidity And Mortality ◽  
High Morbidity ◽  
Screening Strategies ◽  
Proteomics Study ◽  
Efficient Screening ◽  
Potential Biomarkers

AbstractColorectal cancer (CRC) is a malignant tumour with high morbidity and mortality worldwide. Efficient screening strategies for CRC and pre-cancerous lesions will promote early medical intervention and treatment, thus reducing morbidity and mortality. Proteins are generally considered key biomarkers of cancer. Herein, we performed a quantitative, tissue-original proteomics study in a cohort of ninety patients from pre-cancerous to cancerous conditions by liquid chromatography-tandem mass spectrometry. A total of 134,812 peptides, 8,697 proteins, 2,355 (27.08%) union differentially expressed proteins (DEPs), and 409 shared DEPs (compared with adjacent tissues) were identified. The number of DEPs showed a positive correlation with increasing severity of illness. The union and shared DEPs were both enriched in the KEGG pathway of focal adhesion, metabolism of xenobiotics by cytochrome P450, and drug metabolism – cytochrome P450. Among the 2,355 union DEPs, 32 were selected for identification and validation by multiple reaction monitoring from twenty plasma specimens. Of these, three proteins, transferrin receptor protein 1 (TFR1), adenosylhomocysteinase (SAHH), and immunoglobulin heavy variable 3-7 (HV307), were significantly differentially expressed and displayed the same expression pattern in plasma as observed in the tissue data. In conclusion, TFR1, SAHH, and HV307 may be considered as potential biomarkers for screening of CRC.SignificanceCRC is a malignant tumour with high morbidity and mortality worldwide. Efficient screening strategies for CRC and pre-cancerous lesions can play an important role in addressing the issue of high morbidity and mortality. Screening of molecular biomarkers provide a non-invasive, cost-effective and effective approach. Proteins are generally considered key molecular biomarkers of cancer. Our study reports a quantitative proteomics analysis of protein biomarkers for colorectal cancer (CRC) and adenomatous polyps and identifies TFR1, SAHH, and HV307 as potential biomarkers for screening. The research makes a significant contribution to the literature because whereas mass spectrometry-based proteomics research has been widely used for clinical research, its application to clinical translation is lacking as parallel specimens ranging from pre-cancerous to cancerous tissues, according to the degree of disease progression, have not been readily assessed.

Family history of colorectal adenomatous polyps as a risk factor for colorectal cancer

2000 ◽  
Vol 36 (16) ◽  
pp. 2111-2114 ◽  
Author(s):  
H Nakama ◽  
B Zhang ◽  
K Fukazawa ◽  
A.S.M Abdul Fattah
Keyword(s):  
Colorectal Cancer ◽  
Risk Factor ◽  
Family History ◽  
Adenomatous Polyps ◽  
History Of

scholarly journals Development of a prognostic index and screening of potential biomarkers based on immunogenomic landscape analysis of colorectal cancer

Aging ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 5832-5857 ◽  
Author(s):  
Kang Lin ◽  
Jun Huang ◽  
Hongliang Luo ◽  
Chen Luo ◽  
Xiaojian Zhu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Prognostic Index ◽  
Landscape Analysis ◽  
Potential Biomarkers

scholarly journals Non-invasive colorectal cancer screening

2016 ◽  
Vol 85 (2) ◽  
pp. 29-31
Author(s):  
Melissa Holdren ◽  
Brittany Deller ◽  
Kevin Braden
Keyword(s):  
Colorectal Cancer ◽  
Developmental Process ◽  
Population Based ◽  
Adenomatous Polyps ◽  
Morbidity And Mortality ◽  
Screening Tests ◽  
Average Risk ◽  
Screening Programs ◽  
Asymptomatic Patients ◽  
Advanced Adenomas

Colorectal cancer (CRC) is a major cause of morbidity and mortality throughout the world and is the second most common cause of Canadian cancer-related deaths in men and the third most common in women. Most CRC appears to arise from the gradual development and advancement of colonic adenomatous polyps to cancerous tissue. This developmental process of CRC is the rationale for screening programs which aim to reduce CRC-related morbidity and mortality by early detection and removal of adenomatous polyps, specifically advanced adenomas. Although both the gFOBT and FIT function to detect occult bleeding in asymptomatic patients at average risk for CRC development, the mechanisms of these screening tests are distinct. gFOBT works by detecting the peroxidase activity of heme whereas FIT selectively detects human hemoglobin. The sensitivity in detecting CRC is higher for the FIT, with sensitivity of 0.79 compared to gFOBT with sensitivity of 0.36, they have similar specificities of 0.94 and 0.96, respectively. Currently, both the gFOBT and FIT are strongly recommended across Canada, with all provinces using the FIT, apart from Ontario and Manitoba which currently use the gFOBT to screen asymptomatic patients for CRC. A newer test, the sDNA test, identifies mutations in DNA that are shed by both adenomatous polyps and CRC cells. The sDNA test is more sensitive (0.92 95% CI 0.83-0.98) than both the gFOBT and FIT, however, is less specific and more expensive. Further data surrounding the sDNA test will be required prior to its implementation and recommendation for population based CRC screening in Canada. 

scholarly journals Expression of tumor pyruvate kinase M2 isoform in plasma and stool of patients with colorectal cancer or adenomatous polyps

2019 ◽  
Author(s):  
Farideh Rigi ◽  
Aliakbar Jannatabad ◽  
Azra Izanloo ◽  
Reza Roshanravan ◽  
Hamid Reza Hashemian ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Pyruvate Kinase ◽  
Sensitivity And Specificity ◽  
Adenomatous Polyps ◽  
Plasma Samples ◽  
Proliferating Cells ◽  
Pyruvate Kinase M2 ◽  
Specificity And Sensitivity ◽  
Tumor Group ◽  
Stool Samples

Abstract Background: Tumor pyruvate kinase M2 isoform (tM2-PK), which is an isoform of PK-glycolytic enzyme and appears on the surface of cancerous proliferating cells, has been used as a diagnostic biomarker for colorectal cancer (CRC). The aim of this study was to evaluate the tM2-PK measurement test for the diagnosis of CRCs and adenomatous polyps in plasma and stool samples in an Iranian population. Methods: In this prospective study, a total of 226 stool and 178 plasma samples were received from patients referred to colonoscopy units. tM2-PK enzyme was measured using two separate ScheBo-Biotech-AG ELISA kits for stool and plasma samples. Results: At the cut-off value of 4 U/ml, in tumor group, the sensitivity of fecal tM2-PK test was 100% and the specificity was 68%, and in polyp group, the sensitivity and specificity were 87% and 68%, respectively. At the cut-off value of 15 U/ml in tumor group, the sensitivity of plasma tM2-PK test was 98% and specificity was 74% and in polyp group the sensitivity and specificity were 98% and 74%, respectively. Based on our results, a cut-off range of 4.8-8 U/ml and >8 U/ml could be used to detect polyp and tumor in stool samples, respectively. Similarly, a cut-off range of 19-25 U/ml and >25 U/ml is recommended in plasma samples for polyp and tumor detection, respectively. Conclusions: This study revealed a high specificity and sensitivity of tM2-PK test for stool and plasma samples in patients with CRC and polyps suggesting it as a non-invasive assay to diagnose CRC and adenomatous polyps.

scholarly journals Analysis of cancer-related mutations in extracellular vesicles RNA by Droplet Digital™ PCR

BioTechniques ◽  
2020 ◽  
Vol 69 (2) ◽  
pp. 99-107
Author(s):  
Soo Ann Yap ◽  
Agnieszka Münster-Wandowski ◽  
Anika Nonnenmacher ◽  
Ulrich Keilholz ◽  
Sandra Liebs
Keyword(s):  
Colorectal Cancer ◽  
Tumor Progression ◽  
Extracellular Vesicles ◽  
Liquid Biopsy ◽  
Mek Inhibitor ◽  
Diagnostic Information ◽  
Braf V600e ◽  
Plasma Samples ◽  
Differential Centrifugation ◽  
Potential Biomarkers

Extracellular vesicles (EVs) are taking their place as potential biomarkers in the field of liquid biopsy. In this study, EVs were isolated from plasma samples of 31 patients with colorectal cancer and melanoma via differential centrifugation and Droplet Digital™ PCR (Bio-Rad, CA, USA) was used to profile BRAF V600E/K, KRAS G12A/C/D/V and KRAS G13D mutations from EV-derived cDNA. The concordance rates with corresponding tissue were 54% and 44% in the colorectal cancer and melanoma cohort, respectively. Two patients displayed mutations in EVs not previously detected in tissue as evidence for emerging molecular resistance to anti-EGFR and BRAF/MEK inhibitor therapy prior to radiological evidence of tumor progression. We concluded that EV-derived nucleic acids may provide clinically relevant diagnostic information and mirror evolution of the disease.

Sign in / Sign up

Export Citation Format

Share Document